|
Oct 3
|
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
|
|
Oct 3
|
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
|
|
Oct 1
|
Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend
|
|
Sep 30
|
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
|
|
Sep 27
|
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
|
|
Sep 27
|
Dow Rises to Record; Chinese Indexes Post Best Week in Years
|
|
Sep 27
|
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
|
|
Sep 27
|
FDA approves new Bristol Myers Squibb schizophrenia drug
|
|
Sep 27
|
Bristol-Myers Stock Gains on FDA Approval for New Schizophrenia Drug
|
|
Aug 10
|
Bristol-Myers Squibb Company's (NYSE:BMY) recent 4.2% pullback adds to one-year year losses, institutional owners may take drastic measures
|
|
Aug 8
|
Big Pharma Cuts R&D, Sending Shudders Through Industry
|
|
Jul 29
|
Big Pharma Rallies and Moves Past Obesity
|
|
Jul 27
|
Why Wall Street is unfazed by Medicare drug pricing threat
|
|
Jul 26
|
Stocks to Watch Friday: DexCom, 3M, Coinbase, Charter
|
|
Jul 26
|
Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
|
|
Jul 25
|
June PCE, Bristol Myers Squibb earnings: What to watch Friday
|
|
Jun 18
|
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
|
|
Jun 18
|
Bristol Myers Squibb Announces Dividend
|
|
Jun 13
|
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
|
|
Apr 21
|
Is Bristol-Myers Squibb (NYSE:BMY) Using Too Much Debt?
|